Pharmacological characterisation of the somatostatin analogue TT-232: Effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The putative anti-inflammatory and anti-nociceptive activity of the heptapeptide somatostatin analogue TT-232 (D-Phe-Cys-Tyr-D-Thr-Lys-Cys-Thr-NH2) was investigated in the rat and mouse, as well as its effect on neuropathic hyperalgesia, gastric ulceration and the release of sensory neuropeptides. In the rat, carrageenin-induced paw oedema was inhibited dose dependently by TT-232 (3×2.5-20 μg/kg i.v.). Evans blue accumulation induced by intraarticular bradykinin injection (0.5 nmol in 0.1 ml) was slightly, but significantly inhibited by a single TT-232 dose (5-20 μg/kg). Cutaneous neutrophil accumulation over a 3-h period after intradermal (i.d.) injection of carrageenin (1 mg/site) or interleukin 1β (IL-1β, 3 pmol/site) was inhibited significantly by TT-232 (3×80 μg/kg i.v.), while diclofenac (3×10 mg/kg i.v.) elicited significant inhibition only in the IL-1β test. In the mouse, TT-232 potently decreased oedema formation induced by 2.5% capsaicin applied topically to the ear. Mechano-nociception in the rat hind-paw during neuropathic pain induced by partial sciatic nerve injury (model of Seltzer) was measured using the Randall-Selitto test. TT-232 (5-20 μg/kg i.p. on the 7th day after the operation) dose-dependently inhibited the mechano-nociceptive hyperalgesia. In vitro release of substance P (SP), calcitonin gene-related peptide (CGRP) and somatostatin from the isolated rat trachea in response to electrical field stimulation (40 V, 0.1 ms, 10 Hz, 120 s) of its nervous elements was inhibited significantly by 500 nM TT-232. The role of G protein-coupled receptors in the effect of TT-232 was indicated by the prevention of its inhibitory action on the release of sensory neuropeptides by incubation the tissue for 1 or 6 h with pertussis toxin (100 ng/ml). The release of sensory neuropeptides to in response to electrical nerve stimulation was not inhibited by a potent tyrosine kinase inhibitor, genistein (50 μM). TT-232 (up to 5 mg/kg i.p.) did not induce mucosal lesions in either the stomach or the duodenum. These data suggest that TT-232, a somatostatin analogue devoid of endocrine effects, is a promising lead molecule in the search for novel, broad-spectrum anti-inflammatory and analgesic agents.

Original languageEnglish
Pages (from-to)142-150
Number of pages9
JournalNaunyn-Schmiedeberg's Archives of Pharmacology
Volume366
Issue number2
DOIs
Publication statusPublished - 2002

Fingerprint

Hyperalgesia
Somatostatin
Pharmacology
Inflammation
Neuropeptides
Interleukin-1
Carrageenan
Electric Stimulation
Edema
Stomach
Anti-Inflammatory Agents
TT2-32
Intra-Articular Injections
Intradermal Injections
Evans Blue
Nociception
Calcitonin Gene-Related Peptide
Genistein
Diclofenac
Interleukin-3

Keywords

  • Anti-inflammatory effects
  • Inflammation
  • Inflammatory mediators
  • Neuropeptides
  • Somatostatin
  • TT-232

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{ec42bfc3804d46b8b76e57e2ce0e7181,
title = "Pharmacological characterisation of the somatostatin analogue TT-232: Effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia",
abstract = "The putative anti-inflammatory and anti-nociceptive activity of the heptapeptide somatostatin analogue TT-232 (D-Phe-Cys-Tyr-D-Thr-Lys-Cys-Thr-NH2) was investigated in the rat and mouse, as well as its effect on neuropathic hyperalgesia, gastric ulceration and the release of sensory neuropeptides. In the rat, carrageenin-induced paw oedema was inhibited dose dependently by TT-232 (3×2.5-20 μg/kg i.v.). Evans blue accumulation induced by intraarticular bradykinin injection (0.5 nmol in 0.1 ml) was slightly, but significantly inhibited by a single TT-232 dose (5-20 μg/kg). Cutaneous neutrophil accumulation over a 3-h period after intradermal (i.d.) injection of carrageenin (1 mg/site) or interleukin 1β (IL-1β, 3 pmol/site) was inhibited significantly by TT-232 (3×80 μg/kg i.v.), while diclofenac (3×10 mg/kg i.v.) elicited significant inhibition only in the IL-1β test. In the mouse, TT-232 potently decreased oedema formation induced by 2.5{\%} capsaicin applied topically to the ear. Mechano-nociception in the rat hind-paw during neuropathic pain induced by partial sciatic nerve injury (model of Seltzer) was measured using the Randall-Selitto test. TT-232 (5-20 μg/kg i.p. on the 7th day after the operation) dose-dependently inhibited the mechano-nociceptive hyperalgesia. In vitro release of substance P (SP), calcitonin gene-related peptide (CGRP) and somatostatin from the isolated rat trachea in response to electrical field stimulation (40 V, 0.1 ms, 10 Hz, 120 s) of its nervous elements was inhibited significantly by 500 nM TT-232. The role of G protein-coupled receptors in the effect of TT-232 was indicated by the prevention of its inhibitory action on the release of sensory neuropeptides by incubation the tissue for 1 or 6 h with pertussis toxin (100 ng/ml). The release of sensory neuropeptides to in response to electrical nerve stimulation was not inhibited by a potent tyrosine kinase inhibitor, genistein (50 μM). TT-232 (up to 5 mg/kg i.p.) did not induce mucosal lesions in either the stomach or the duodenum. These data suggest that TT-232, a somatostatin analogue devoid of endocrine effects, is a promising lead molecule in the search for novel, broad-spectrum anti-inflammatory and analgesic agents.",
keywords = "Anti-inflammatory effects, Inflammation, Inflammatory mediators, Neuropeptides, Somatostatin, TT-232",
author = "E. Pint{\'e}r and Z. Helyes and J. N{\'e}meth and R. P{\'o}rsz{\'a}sz and G. Pethő and M. Th{\'a}n and G. K{\'e}ri and Anik{\'o} Horv{\'a}th and Bal{\'a}zs Jakab and J. Szolcs{\'a}nyi",
year = "2002",
doi = "10.1007/s00210-002-0563-9",
language = "English",
volume = "366",
pages = "142--150",
journal = "Naunyn-Schmiedeberg's Archives of Pharmacology",
issn = "0028-1298",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Pharmacological characterisation of the somatostatin analogue TT-232

T2 - Effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia

AU - Pintér, E.

AU - Helyes, Z.

AU - Németh, J.

AU - Pórszász, R.

AU - Pethő, G.

AU - Thán, M.

AU - Kéri, G.

AU - Horváth, Anikó

AU - Jakab, Balázs

AU - Szolcsányi, J.

PY - 2002

Y1 - 2002

N2 - The putative anti-inflammatory and anti-nociceptive activity of the heptapeptide somatostatin analogue TT-232 (D-Phe-Cys-Tyr-D-Thr-Lys-Cys-Thr-NH2) was investigated in the rat and mouse, as well as its effect on neuropathic hyperalgesia, gastric ulceration and the release of sensory neuropeptides. In the rat, carrageenin-induced paw oedema was inhibited dose dependently by TT-232 (3×2.5-20 μg/kg i.v.). Evans blue accumulation induced by intraarticular bradykinin injection (0.5 nmol in 0.1 ml) was slightly, but significantly inhibited by a single TT-232 dose (5-20 μg/kg). Cutaneous neutrophil accumulation over a 3-h period after intradermal (i.d.) injection of carrageenin (1 mg/site) or interleukin 1β (IL-1β, 3 pmol/site) was inhibited significantly by TT-232 (3×80 μg/kg i.v.), while diclofenac (3×10 mg/kg i.v.) elicited significant inhibition only in the IL-1β test. In the mouse, TT-232 potently decreased oedema formation induced by 2.5% capsaicin applied topically to the ear. Mechano-nociception in the rat hind-paw during neuropathic pain induced by partial sciatic nerve injury (model of Seltzer) was measured using the Randall-Selitto test. TT-232 (5-20 μg/kg i.p. on the 7th day after the operation) dose-dependently inhibited the mechano-nociceptive hyperalgesia. In vitro release of substance P (SP), calcitonin gene-related peptide (CGRP) and somatostatin from the isolated rat trachea in response to electrical field stimulation (40 V, 0.1 ms, 10 Hz, 120 s) of its nervous elements was inhibited significantly by 500 nM TT-232. The role of G protein-coupled receptors in the effect of TT-232 was indicated by the prevention of its inhibitory action on the release of sensory neuropeptides by incubation the tissue for 1 or 6 h with pertussis toxin (100 ng/ml). The release of sensory neuropeptides to in response to electrical nerve stimulation was not inhibited by a potent tyrosine kinase inhibitor, genistein (50 μM). TT-232 (up to 5 mg/kg i.p.) did not induce mucosal lesions in either the stomach or the duodenum. These data suggest that TT-232, a somatostatin analogue devoid of endocrine effects, is a promising lead molecule in the search for novel, broad-spectrum anti-inflammatory and analgesic agents.

AB - The putative anti-inflammatory and anti-nociceptive activity of the heptapeptide somatostatin analogue TT-232 (D-Phe-Cys-Tyr-D-Thr-Lys-Cys-Thr-NH2) was investigated in the rat and mouse, as well as its effect on neuropathic hyperalgesia, gastric ulceration and the release of sensory neuropeptides. In the rat, carrageenin-induced paw oedema was inhibited dose dependently by TT-232 (3×2.5-20 μg/kg i.v.). Evans blue accumulation induced by intraarticular bradykinin injection (0.5 nmol in 0.1 ml) was slightly, but significantly inhibited by a single TT-232 dose (5-20 μg/kg). Cutaneous neutrophil accumulation over a 3-h period after intradermal (i.d.) injection of carrageenin (1 mg/site) or interleukin 1β (IL-1β, 3 pmol/site) was inhibited significantly by TT-232 (3×80 μg/kg i.v.), while diclofenac (3×10 mg/kg i.v.) elicited significant inhibition only in the IL-1β test. In the mouse, TT-232 potently decreased oedema formation induced by 2.5% capsaicin applied topically to the ear. Mechano-nociception in the rat hind-paw during neuropathic pain induced by partial sciatic nerve injury (model of Seltzer) was measured using the Randall-Selitto test. TT-232 (5-20 μg/kg i.p. on the 7th day after the operation) dose-dependently inhibited the mechano-nociceptive hyperalgesia. In vitro release of substance P (SP), calcitonin gene-related peptide (CGRP) and somatostatin from the isolated rat trachea in response to electrical field stimulation (40 V, 0.1 ms, 10 Hz, 120 s) of its nervous elements was inhibited significantly by 500 nM TT-232. The role of G protein-coupled receptors in the effect of TT-232 was indicated by the prevention of its inhibitory action on the release of sensory neuropeptides by incubation the tissue for 1 or 6 h with pertussis toxin (100 ng/ml). The release of sensory neuropeptides to in response to electrical nerve stimulation was not inhibited by a potent tyrosine kinase inhibitor, genistein (50 μM). TT-232 (up to 5 mg/kg i.p.) did not induce mucosal lesions in either the stomach or the duodenum. These data suggest that TT-232, a somatostatin analogue devoid of endocrine effects, is a promising lead molecule in the search for novel, broad-spectrum anti-inflammatory and analgesic agents.

KW - Anti-inflammatory effects

KW - Inflammation

KW - Inflammatory mediators

KW - Neuropeptides

KW - Somatostatin

KW - TT-232

UR - http://www.scopus.com/inward/record.url?scp=0035992655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035992655&partnerID=8YFLogxK

U2 - 10.1007/s00210-002-0563-9

DO - 10.1007/s00210-002-0563-9

M3 - Article

C2 - 12122501

AN - SCOPUS:0035992655

VL - 366

SP - 142

EP - 150

JO - Naunyn-Schmiedeberg's Archives of Pharmacology

JF - Naunyn-Schmiedeberg's Archives of Pharmacology

SN - 0028-1298

IS - 2

ER -